Clinical trials: Melanoma
Urinary Bladder Cancer, Melanoma
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung…
- Conditions
- Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT03132922
- Testing
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
- Where
- 11 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- USWM CT, LLC
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
- Trial name
- NCT03739931
- Testing
- mRNA-2752, Durvalumab
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 134 people
- Sponsor
- ModernaTX, Inc.
Skin Lesion, Melanoma
Investigating the Clinical Utility of the MDS
The purpose of this study is to establish the clinical utility of the Melanoma Detection System (MDS).
- Conditions
- Skin Lesion, Melanoma, Moles
- Trial name
- OMS002_UK (NCT03109327)
- Testing
- Melanoma Detection System -MDS
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Orlucent, Inc
Cancer
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of daily oral administration of eFT508.
- Trial name
- NCT02605083
- Testing
- eFT508
- Where
- 4 sites in United States
- Volunteers
- 66 people
- Sponsor
- Effector Therapeutics
Stage IV Melanoma
Investigating Participation Patterns Among Stage IV Melanoma Patients
Clinical trials, specifically focused on stage IV melanoma, are crucial in assessing the safety and efficacy of new treatments for this disease.
- Trial name
- NCT06093594
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Stage IV Melanoma, Metastatic Melanoma
Immunotherapy Study for Patients With Stage IV Melanoma
The purpose of this study is to examine the effectiveness of immune checkpoint inhibitors (drugs called ipilimumab, nivolumab, or pembrolizumab), either given alone, or in combination with the experimental immunotherapy drug…
- Trial name
- NCT02054520
- Testing
- HyperAcute®-Melanoma (HAM) Immunotherapy, Ipilimumab, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- NewLink Genetics Corporation
Solid Tumors
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
This is an open-label, multicenter Phase 2 study evaluating Navlimetostat (BMS-986504) in participants with advanced and/or metastatic solid tumors that have MTAP deletion.
- Trial name
- NCT07492680
- Testing
- Navlimetostat, Daraxonrasib, Temozolomide
- Where
- 58 sites in United States, Belgium and 11 more
- Volunteers
- 254 people
- Sponsor
- Bristol-Myers Squibb
Melanoma (Skin)
Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. Photodynamic therapy may be effective in treating melanoma.
- Trial name
- NCT00007969
- Testing
- Detox-B adjuvant, verteporfin
- Where
- 6 sites in United States
- Sponsor
- QLT Inc.
Melanoma
Study of HL-085 in NRAS Mutant Advanced Melanoma
This is a phase I/II, open-label, dose escalation study to evaluate tolerability, safety, pharmacokinetics and efficacy in patients with NRAS mutant advanced melanoma .
- Trial name
- NCT03973151
- Testing
- HL-085
- Where
- 2 sites in China
- Volunteers
- 42 people
- Sponsor
- Shanghai Kechow Pharma, Inc.
Melanoma
Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.
Non-interventional (observational) cohort prospective real life study with primary and secondary data collection from patients on adjuvant treatment with dabrafenib + trametinib in patients with completely resected high-risk…
- Trial name
- LEAD Melanoma (NCT04961619)
- Testing
- dabrafenib, trametinib
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Cancer
In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation
This is a Phase I/II study to investigate the feasibility of creating a personalized therapeutic cancer vaccine within the body. A vaccine contains a source of tumor antigen and an adjuvant.
- Trial name
- NCT00861107
- Testing
- AlloStim-7, percutaneous tumor cryoablation, AlloStim8 or AlloStim-9
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mirror Biologics, Inc.
Melanoma (Skin)
Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage II, stage III, or stage IV melanoma.
- Trial name
- NCT00010309
- Testing
- MART-1 antigen, gp100 antigen
- Where
- 3 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Neoplasms
BAY1238097, First in Man
This is the first study where BAY1238097 is given to humans. Impact of the study is to evaluate if patients with advanced cancer show clinical benefit under the treatment with BET(Bromodomain and extraterminal domain family )…
- Trial name
- NCT02369029
- Testing
- BAY 1238097
- Where
- 6 sites in United States, Finland and 4 more
- Volunteers
- 8 people
- Sponsor
- Bayer
Melanoma
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
This is a phase 2, open-label, single-arm, multicenter clinical trial designed to evaluate the efficacy and safety of talimogene laherparepvec in combination with pembrolizumab following disease progression on prior…
- Trial name
- NCT04068181
- Testing
- Talimogene laherparepvec, Pembrolizumab
- Where
- 46 sites in United States, Australia and 9 more
- Volunteers
- 72 people
- Sponsor
- Amgen
Solid Tumors, Metastatic Melanoma
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of single agent lomvastomig (RO7121661), an anti PD-1 (programmed death-1) and TIM-3 (T-cell immunoglobulin and mucin domain 3)…
- Conditions
- Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
- Trial name
- NCT03708328
- Testing
- Lomvastomig
- Where
- 17 sites in United States, Denmark and 4 more
- Volunteers
- 134 people
- Sponsor
- Hoffmann-La Roche
Unresected Stage IIIb to IVM1c Melanoma
Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma
The study is a phase 2, multi centered, single arm study designed to evaluate the correlation between cluster of differentiation 8-positive (CD8+) cell density and objective response rate in adults with unresected stage IIIB to…
- Trial name
- TVEC-325 (NCT02366195)
- Testing
- Talimogene Laherparepvec
- Where
- 42 sites in United States, Austria and 11 more
- Volunteers
- 112 people
- Sponsor
- Amgen
Melanoma
Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma
In this open-label study of patients with advanced melanoma 20 evaluable patients will be recruited. The drug substance, AGI-101H, is a whole cell, allogeneic melanoma vaccine, representing a mixture (1:1 ratio) of two…
- Trial name
- NCT00716495
- Testing
- AGI-101H Vaccine
- Where
- Poland
- Volunteers
- 5 people
- Sponsor
- AGIRx Ltd.
Metastatic Solid Tumor, Advanced Solid Tumor
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.
- Trial name
- NCT05479812
- Testing
- WTX-124, pembrolizumab
- Where
- 14 sites in United States
- Volunteers
- 156 people
- Sponsor
- Werewolf Therapeutics, Inc.
Advanced Cancer
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.
- Trial name
- NCT04148937
- Testing
- LY3475070, Pembrolizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Melanoma
Safety of TKI258 in Advanced/Metastatic Melanoma Subjects
This study is an open-label, dose-escalating study to delineate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TKI258. Pharmacokinetics and pharmacodynamics will be performed on all subjects.
- Trial name
- NCT00303251
- Testing
- TKI258
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.